Oncotelic Therapeutics (OTCQB: OTLC), together with Sapu Nano, announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences validating its proprietary Deciparticle(TM) nanoparticle platform through the development of Sapu003, an investigational intravenous everolimus formulation currently being evaluated in an ongoing Phase 1b clinical trial. The publication details the platform’s formulation design, scalable cGMP manufacturing process, product stability and preclinical performance, while demonstrating its potential to enable intravenous delivery of poorly water-soluble therapeutic compounds.
The company said the research also supports broader applications for the Deciparticle(TM) platform beyond everolimus, including additional hydrophobic drug candidates. Sapu003 is currently being evaluated in a Phase 1b dose-escalation study in patients with advanced mTOR-sensitive solid tumors to assess its safety, pharmacokinetics and preliminary antitumor activity in combination with exemestane.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer